Kathleen W Turnbull Selected Research

Stomatitis

1/2014

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kathleen W Turnbull Research Topics

Disease

1	Anemia 01/2014
1	Breast Neoplasms (Breast Cancer) 01/2014
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2014
1	Diarrhea 01/2014
1	Lung Neoplasms (Lung Cancer) 01/2014
1	Nausea 01/2014
1	Neoplasms (Cancer) 01/2014
1	Stomatitis 01/2014

Drug/Important Bio-Agent (IBA)

1	temsirolimus FDA Link 01/2014
1	neratinibIBA 01/2014
1	Trastuzumab (Herceptin)FDA Link 01/2014
1	Tyrosine Kinase InhibitorsIBA 01/2014
1	Pharmaceutical PreparationsIBA 01/2014
1	Epidermal Growth Factor (EGF)IBA 01/2014
1	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 01/2014
1	TOR Serine-Threonine KinasesIBA 01/2014
1	ErbB Receptors (EGF Receptor)IBA 01/2014